A Clinical Evaluation of Absorb? BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesion (ABSORB III)
The pivotal trial to support the US pre-market approval (PMA) of Absorb BVS. ABSORB III will evaluate the safety and effectiveness of the Absorb BVS System compared to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels. Phone: 904-244-2655 Email: email@example.com
KeywordsAbsorb BVS, de novo Native Coronary Artery Lesion, ABSORB III, Vascular Scaffold, Everolimus Eluting
Principal InvestigatorTHEODORE BASS, PROF & PRG DIR
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.